Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study to Assess the Safety of APD-791 When Co-administered With Aspirin

Trial Profile

Phase I Study to Assess the Safety of APD-791 When Co-administered With Aspirin

Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Temanogrel (Primary) ; Aspirin; Clopidogrel
  • Indications Acute coronary syndromes
  • Focus Adverse reactions
  • Acronyms PR1C; TG1C
  • Sponsors Ildong Pharmaceutical
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Jun 2018 Status changed to discontinued.
    • 12 May 2014 According to the Arena Pharmaceuticals media release, Ildong Pharmaceutical has initiated dosing in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top